Treatment of Parathyroid Cancer: Current Status and Near-Term Prospects

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Parathyroid cancer (PС) is a rare malignant neoplasm of the endocrine system, characterized by a severe course due to the development of life-threatening hypercalcemia. Despite a relatively high survival rate, recurrence occurs about half the time. The aggressive course of PС is associated with both local spread of the process and distant metastasis. With the exception of isolated cases, cytotoxic chemo- and radiotherapy are inefficacious, and treatment protocols have not been developed. Therefore the only effective way is the surgical removal of secondary lesions, which is not always technically feasible and is associated with a high risk of postoperative complications. The literature describes individual cases of successful use of targeted therapy, as well as immunotherapy in the form of therapeutic vaccination to induce an immune response against parathyroid hormone (PTH) and block immune checkpoint. A promising direction of study is the tumor immunoenvironment, which has both diagnostic and prognostic value in relation to the likelihood of the spread of the tumor process. In this review, we describe the main directions in the treatment of PC, including disseminated forms, the possibilities of immunotherapy will be considered in details.

Full Text

Restricted Access

About the authors

Ekaterina I. Kim

Endocrinology Research Centre

Author for correspondence.
Email: kat-alex2007@mail.ru
ORCID iD: 0000-0001-7879-8495
SPIN-code: 1628-2139

MD, PhD Student

Russian Federation, Moscow

Julia A. Krupinova

Endocrinology Research Centre

Email: j.krupinova@gmail.com
ORCID iD: 0000-0001-7963-5022
SPIN-code: 6279-8247

MD, PhD

Russian Federation, Moscow

Pavel V. Belousov

Endocrinology Research Centre

Email: belousp@gmail.com
ORCID iD: 0000-0002-8216-517X
SPIN-code: 5531-6435

Senior Research Associate

Russian Federation, Moscow

Kseniya А. Trutneva

Endocrinology Research Centre

Email: trutneva-k@mail.ru
ORCID iD: 0000-0003-4748-6362

Researcher, PhD in Biology

Russian Federation, Moscow

Natalya G. Mokrysheva

Endocrinology Research Centre

Email: mokrisheva.natalia@endocrincentr.ru
ORCID iD: 0000-0002-9717-9742
SPIN-code: 5624-3875

MD, PhD, Professor

Russian Federation, Moscow

References

  1. Hundahl SA, Fleming ID, Fremgen AM, et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538–544. doi: https://doi.org/10.1002/(SICI)1097-0142(19990801)86:3<538::AID-CNCR25>3.0.CO;2-k
  2. Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736–1741. doi: https://doi.org/10.1002/cncr.22599
  3. Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145–158. doi: https://doi.org/10.1016/S0140-6736(09)60507-9
  4. Obregón LM, Taylor MF, Mir G, et al. Parathyroidectomy for parathyroid carcinoma in renal transplantation. Transplant Proc. 2005;37(2):973–976. doi: https://doi.org/10.1016/j.transproceed.2004.12.305
  5. Machado NN, Wilhelm SM. Parathyroid cancer: A review. Cancers (Basel). 2019;11(11):1676. doi: https://doi.org/10.3390/cancers11111676
  6. Ryhänen EM, Leijon H, Metso S, et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017;56(7):991–1003. doi: https://doi.org/10.1080/0284186X.2017.1306103
  7. Brown S, O’Neill C, Suliburk J, et al. Parathyroid carcinoma: Increasing incidence and changing presentation. ANZ J Surg. 2011;81(7–8):528–532. doi: https://doi.org/10.1111/j.1445-2197.2010.05594.x
  8. Van der Zwan JM, Mallone S, van Dijk B, et al. Carcinoma of endocrine organs : Results of the RARECARE project. Eur J Cancel. 2012;48(13):1923–1931. doi: https://doi.org/10.1016/j.ejca.2012.01.029
  9. Sadler C, Gow KW, Beierle EA, et al. Parathyroid carcinoma in more than 1,000 patients: A population-level analysis. Surgery. 2014;156(6):1622–1630. doi: https://doi.org/10.1016/j.surg.2014.08.069
  10. Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer: A review of 95 cases. World J Surg. 1992;16(4):724–731. doi: https://doi.org/10.1007/BF02067369
  11. Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: A 22-year experience. Head Neck. 2004;26(8):716–726. doi: https://doi.org/10.1002/hed.20049
  12. Iacobone M, Lumachi F, Favia G. Up-to-date on parathyroid carcinoma: Analysis of an experience of 19 cases. J Surg Oncol. 2004;88(4):223–228. doi: https://doi.org/10.1002/jso.20152
  13. Rodrigo JP, Hernandez-Prera JC, Randolph GW, et al. Parathyroid cancer : An update. Cancer Treat Rev. 2020;86:102012. doi: https://doi.org/10.1016/j.ctrv.2020.102012
  14. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol. 2001;2(4):347–354. doi: https://doi.org/10.1007/s11864-001-0028-2
  15. Shifrin A, LiVolsi V, Shifrin-Douglas S, et al. Primary and metastatic parathyroid malignancies: A rare or underdiagnosed condition? J Clin Endocrinol Metab. 2015;100(3):E478–E481. doi: https://doi.org/10.1210/jc.2014-2760
  16. Salcuni AS, Cetani F, Guarnieri V, et al. Parathyroid carcinoma. Best Pract Res Clin Endocrinol Metab. 2018;32(6):877–889. doi: https://doi.org/10.1016/j.beem.2018.11.002
  17. Erickson LA, Mete O, Juhlin CC, et al. Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocr Pathol. 2022;33(1):64–89. doi: https://doi.org/10.1007/s12022-022-09709-1
  18. Cetani F, Marcocci C, Torregrossa L, et al. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer. 2019;26(7):R441–R464. doi: https://doi.org/10.1530/ERC-19-0135
  19. Erickson LA, Mete O. Immunohistochemistry in Diagnostic Parathyroid Pathology. Endocr Pathol. 2018;29(2):113–129. doi: https://doi.org/10.1007/s12022-018-9527-6
  20. Juhlin CC, Nilsson IL, Lagerstedt-Robinson K, et al. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center. Mod Pathol. 2019;32(8):1082–1094. doi: https://doi.org/10.1038/s41379-019-0252-6
  21. Xue S, Chen H, Lv C, et al. Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. Clin Endocrinol (Oxf). 2016;85(1):29–36. doi: https://doi.org/10.1111/cen.13055
  22. Asare EA, Sturgeon C, Winchester DJ, et al. Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22(12):3990–3995. doi: https://doi.org/10.1245/s10434-015-4672
  23. Hsu KT, Sippel RS, Chen H, et al. Is central lymph node dissection necessary for parathyroid carcinoma? Surgery. 2014;156(6):1336–1341. doi: https://doi.org/10.1016/j.surg.2014.08.005
  24. Perrier ND, Arnold A, Costa-Guda J, et al. Hereditary endocrine tumours: Current state-of-the-art and research opportunities: New and future perspectives for parathyroid carcinoma. Endocr Relat Cancer. 2020;27(8):T53–T63. doi: https://doi.org/10.1530/ERC-20-0018
  25. Lenschow C, Schrägle S, Kircher S, et al. Clinical Presentation, Treatment, and Outcome of Parathyroid Carcinoma: Results of the NEKAR Retrospective International Multicenter Study. Ann Surg. 2022;275(2):e479–e487. doi: https://doi.org/10.1097/SLA.0000000000004144
  26. Leonard-Murali S, Ivanics T, Kwon DS, et al. Local resection versus radical surgery for parathyroid carcinoma: A National Cancer Database analysis. Eur J Surg Oncol. 2021;47(11):2768–2773. doi: https://doi.org/10.1016/j.ejso.2021.06.026
  27. Shane E. Clinical review 122: Parathyroid Carcinoma. J Clin Endocrinol Metab. 2001;86(2):485–493. doi: https://doi.org/10.1210/jcem.86.2.7207
  28. Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Invest. 2016;39(6):595–606. doi: https://doi.org/10.1007/s40618-016-0447-3
  29. Storvall S, Ryhänen E, Bensch FV, et al. Recurrent Metastasized Parathyroid Carcinoma-Long-Term Remission after Combined Treatments with Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide. JBMR Plus. 2019;3(4):e10114. doi: https://doi.org/10.1002/jbm4.10114
  30. Christakis I, Silva AM, Williams MD, et al. Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years. Pract Radiat Oncol. 2017;7(6):e463–e470. doi: https://doi.org/10.1016/j.prro.2017.05.009
  31. Erovic BM, Goldstein DP, Kim D, et al. Parathyroid cancer: Outcome analysis of 16 patients treated at the princess margaret hospital. Head Neck. 2013;35(1):35–39. doi: https://doi.org/10.1002/hed.22908
  32. Calandra DB, Chejfec G, Foy BK, et al. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery. 1984;96(6):1132–1137.
  33. Bukowski RM, Sheeler L, Cunningham J, et al. Successful Combination Chemotherapy for Metastatic Parathyroid Carcinoma. Arch Intern Med. 1984;144(2):399–400. doi: https://doi.org/10.1001/archinte.1984.00350140229032
  34. Chahinian AP, Holland JF, Nieburgs HE, et al. Metastatic nonfunctioning parathyroid carcinoma: ultrastructural evidence of secretory granules and response to chemotherapy. Am J Med Sci. 1981;282(2):80–84. doi: https://doi.org/10.1097/00000441-198109000-00005
  35. DasGupta R, Shetty S, Keshava SN, et al. Metastatic parathyroid carcinoma treated with radiofrequency ablation: A novel therapeutic modality. Australas Med J. 2014;7(9):372–375. doi: https://doi.org/10.4066/AMJ.2014.2084
  36. Singh RR, Patel KP, Routbort MJ, et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013;15(5):607–622. doi: https://doi.org/10.1016/j.jmoldx.2013.05.003
  37. Kutahyalioglu M, Nguyen HT, Kwatampora L, et al. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019;145(8):1977–1986. doi: https://doi.org/10.1007/s00432-019-02945-9
  38. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1(2):157–162. doi: https://doi.org/10.1038/35101031
  39. Hsieh JJ, Chen D, Wang PI, et al. Genomic Biomarkers of a Randomized Trial Comparing First-Line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol. 2017;71(3):405–414. doi: https://doi.org/10.1016/j.eururo.2016.10.007
  40. Rozhinskaya L, Pigarova E, Sabanova E, et al. Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol Diabetes Metab Case Rep. 2017;2017:16-0113. doi: https://doi.org/10.1530/EDM-16-0113
  41. Schott M, Feldkamp J, Schaltenberg D, et al. Dendritic cell immune-therapy in disseminated parathyroid carcinoma. Lancet. 1999;353(9159):1188–1189. doi: https://doi.org/10.1016/S0140-6736(05)74412-3
  42. Bradwell AR, Harvey TC. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet. 1999;353(9150):370–373. doi: https://doi.org/10.1016/S0140-6736(98)06469-1
  43. Betea D, Bradwell AR, Harvey TC, et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab. 2004;89(7):3413–3420. doi: https://doi.org/10.1210/jc.2003-031911
  44. Sarquis M, Marx SJ, Beckers A, et al. Long-term remission of disseminated parathyroid cancer following immunotherapy. Endocrine. 2020;67(1):204–208. doi: https://doi.org/10.1007/s12020-019-02136-z
  45. Dudley JC, Lin M-T, Le DT, et al. Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res. 2016;22(4):813–820. doi: https://doi.org/10.1158/1078-0432.CCR-15-1678
  46. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207–212. doi: https://doi.org/10.1016/j.coi.2011.12.009
  47. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116(7):1757–1766. doi: https://doi.org/10.1002/cncr.24899
  48. Cancer Research Institute. Timeline of progress. Available from: https://www.cancerresearch.org/immunotherapy/timeline-of-progress (accessed: 22.09.2019).
  49. Park D, Airi R, Sherman M. Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti-PD1 immunotherapy, pembrolizumab. BMJ Case Rep. 2020;13(9):e235293. doi: https://doi.org/10.1136/bcr-2020-235293
  50. Lenschow C, Fuss CT, Kircher S, et al. Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. Front Endocrinol (Lausanne). 2021;12:643328. doi: https://doi.org/10.3389/fendo.2021.643328
  51. Galon J, Lanzi A. Immunoscore and its introduction in clinical practice. Q J Nucl Med Mol Imaging. 2020;64(2):152–161. doi: https://doi.org/10.23736/S1824-4785.20.03249-5
  52. Hu Y, Cui M, Bi Y, et al. Immunocyte density in parathyroid carcinoma is correlated with disease relapse. J Endocrinol Invest. 2020;43(10):1453–1461. doi: https://doi.org/10.1007/s40618-020-01224-6
  53. Mirrakhimov A.E. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci. 2015;7(11):483–493. doi: https://doi.org/10.4103/1947-2714.170600
  54. Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014;99(9):3144–3152. doi: https://doi.org/10.1210/jc.2014-1001
  55. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007;92(10):3803–3808. doi: https://doi.org/10.1210/jc.2007-0585
  56. Koyano H, Shishiba Y, Shimizu T, et al. Successful Treatment by Surgical Removal of Bone Metastasis Producing PTH: New Approach to the Management of Metastatic Parathyroid Carcinoma. Intern Med. 1994;33(11):697–702. doi: https://doi.org/10.2169/internalmedicine.33.697
  57. Iguchi T, Yasui K, Hiraki T, et al. Radiofrequency ablation of functioning lung metastases from parathyroid carcinoma. J Vasc Interv Radiol. 2008;19(3):462–464. doi: https://doi.org/10.1016/j.jvir.2007.12.440
  58. Tochio M, Takaki H, Yamakado K, et al. A Case report of 20 lung radiofrequency ablation sessions for 50 lung metastases from parathyroid carcinoma causing hyperparathyroidism. Cardiovasc Intervent Radiol. 2010;33(3):657–659. doi: https://doi.org/10.1007/s00270-009-9730-4
  59. Artinyan A, Guzman E, Maghami E, et al. Metastatic parathyroid carcinoma to the liver treated with radiofrequency ablation and transcatheter arterial embolization. J Clin Oncol. 2008;26(24):4039–4041. doi: https://doi.org/10.1200/JCO.2007.15.9038
  60. Montenegro FL, Chammas MC, Juliano AG, et al. Ethanol injection under ultrasound guidance to palliate unresectable parathyroid carcinoma. Arq Bras Endocrinol Metabol. 2008;52(4):707–711. doi: https://doi.org/10.1590/s0004-27302008000400019

Supplementary files

There are no supplementary files to display.


Copyright (c) 2022 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies